Amylyx (AMLX) Stock Jumps as Avexitide Cuts Low Blood Sugar Episodes by 55% in Late-Stage Trial

TLDR

• Avexitide cut low blood sugar episodes by 55% versus placebo in a 78-patient late-stage trial
• AMLX stock rose to $31.72, on track to add roughly $1.15 billion to its market value
• Stifel analyst called the result a “best-case scenario” outcome
• TD Cowen projects peak U.S. sales of $2.2 billion for avexitide
• Amylyx launched a $350 million stock offering to fund pre-commercial activities

Amylyx Pharmaceuticals stock surged more than 45% on Tuesday after its experimental drug avexitide sharply reduced dangerous low blood sugar episodes in a late-stage clinical trial. AMLX rose to $31.72 in morning trading.

Amylyx Pharmaceuticals, Inc., AMLX

The 78-patient trial tested avexitide in patients who had undergone Roux-en-Y gastric bypass surgery. The drug reduced hypoglycemic episodes by 55% compared to placebo over 16 weeks, meeting the trial’s main goal.

There are currently no approved treatments for post-bariatric hypoglycemia, a condition that can cause cognitive impairment, loss of consciousness, or seizures.

… Continue reading the full article at the original source below.